1. Home
  2. RDZN vs ANIX Comparison

RDZN vs ANIX Comparison

Compare RDZN & ANIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Roadzen Inc.

RDZN

Roadzen Inc.

HOLD

Current Price

$1.14

Market Cap

122.4M

Sector

Finance

ML Signal

HOLD

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.76

Market Cap

108.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RDZN
ANIX
Founded
2015
1982
Country
United States
United States
Employees
308
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.4M
108.5M
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
RDZN
ANIX
Price
$1.14
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$8.67
AVG Volume (30 Days)
660.1K
312.4K
Earning Date
02-12-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
12.82
EPS
N/A
N/A
Revenue
N/A
$210,000.00
Revenue This Year
$33.77
N/A
Revenue Next Year
$51.46
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.81
$2.32
52 Week High
$2.56
$5.46

Technical Indicators

Market Signals
Indicator
RDZN
ANIX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
RDZN
ANIX

About RDZN Roadzen Inc.

Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express.

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

Share on Social Networks: